Phreesia’s (PHR) Neutral Rating Reiterated at Robert W. Baird

Robert W. Baird reaffirmed their neutral rating on shares of Phreesia (NYSE:PHR) in a research report sent to investors on Tuesday morning, MarketBeat reports. Robert W. Baird currently has a $10.00 price objective on the stock, down from their previous price objective of $25.00.

A number of other research analysts also recently commented on the stock. Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Canaccord Genuity Group reduced their price target on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, December 9th. Citigroup decreased their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, January 9th. Truist Financial set a $24.00 price objective on Phreesia in a report on Thursday, January 8th. Finally, Wells Fargo & Company cut their target price on Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Twelve research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Phreesia Price Performance

PHR stock opened at $8.35 on Tuesday. The business has a 50 day moving average price of $12.07 and a 200 day moving average price of $17.44. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01. The stock has a market cap of $503.18 million, a price-to-earnings ratio of 278.20 and a beta of 0.86. Phreesia has a fifty-two week low of $7.77 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR) last announced its quarterly earnings results on Monday, March 30th. The company reported $0.02 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.05). Phreesia had a net margin of 0.48% and a return on equity of 3.33%. The company had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Equities research analysts anticipate that Phreesia will post -1.1 earnings per share for the current fiscal year.

Insider Activity

In other Phreesia news, insider Evan Roberts sold 6,268 shares of the stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $102,544.48. Following the completion of the sale, the insider directly owned 826,554 shares of the company’s stock, valued at approximately $13,522,423.44. This trade represents a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Amy Beth Vanduyn sold 2,202 shares of Phreesia stock in a transaction that occurred on Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $36,024.72. Following the completion of the transaction, the senior vice president owned 157,349 shares in the company, valued at $2,574,229.64. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 70,358 shares of company stock worth $1,123,569 over the last quarter. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Phreesia

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Phreesia by 8.3% during the 3rd quarter. Vanguard Group Inc. now owns 5,704,786 shares of the company’s stock worth $134,177,000 after buying an additional 437,462 shares during the last quarter. New York State Common Retirement Fund boosted its holdings in shares of Phreesia by 727.1% in the third quarter. New York State Common Retirement Fund now owns 136,856 shares of the company’s stock valued at $3,219,000 after acquiring an additional 120,309 shares in the last quarter. Squarepoint Ops LLC increased its stake in shares of Phreesia by 243.6% during the second quarter. Squarepoint Ops LLC now owns 100,922 shares of the company’s stock worth $2,872,000 after acquiring an additional 71,553 shares during the period. Greenhouse Funds LLLP increased its stake in shares of Phreesia by 16.8% during the third quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after acquiring an additional 557,265 shares during the period. Finally, Bessemer Group Inc. raised its holdings in Phreesia by 1,065.9% during the third quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock worth $13,043,000 after purchasing an additional 506,954 shares in the last quarter. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Analyst take: a MarketBeat piece argues Phreesia may have hit a trough and is well‑positioned to regain growth and market share over time, suggesting upside if execution and demand stabilize. Phreesia Hits Bottom in Q1: Rebound Ahead, Timing Uncertain
• Neutral Sentiment: Several large firms have issued neutral/market‑perform ratings (Robert W. Baird, JPMorgan, Citigroup), signaling limited near‑term conviction rather than outright sell ratings. Phreesia (NYSE:PHR) Earns “Neutral” Rating from Robert W. Baird
• Neutral Sentiment: Citizens JMP reaffirmed a market‑perform view, reflecting tepid near‑term expectations from another sell‑side firm. Citizens JMP Market Perform Reaffirmed
• Neutral Sentiment: Investor comparison coverage contrasts Phreesia with peers (MSP Recovery), providing context but not a clear directional trigger. Phreesia and MSP Recovery Critical Contrast
• Negative Sentiment: Primary catalyst: Phreesia reported its first full‑year profit but issued lower FY2027 revenue guidance, prompting a sharp selloff as investors focused on the reduced top‑line outlook. Phreesia (PHR) Is Down 25.5% After First Full-Year Profit But Lower 2027 Revenue Guidance
• Negative Sentiment: Multiple analysts cut expectations and targets (Canaccord cut its price target to $22; Needham, Stephens and BMO issued more pessimistic views), increasing selling pressure and lowering implied valuation. Needham Lowers Expectations for Phreesia BMO Capital Markets Issues Pessimistic Forecast for Phreesia Needham & Company LLC Has Lowered Expectations for Phreesia
• Negative Sentiment: The stock hit a new one‑year low after the earnings/guide miss, a technical signal that can accelerate outflows from momentum and quant funds. Phreesia Reaches New 1-Year Low After Earnings Miss
• Negative Sentiment: Legal risk: a law firm announced an investigation into potential securities‑law violations tied to prior guidance comments, adding uncertainty and potential headline risk. Investors in Phreesia Warned of Potential Securities Fraud
• Negative Sentiment: Some outlets and analysts pulled recommendations or expressed disappointment in growth guidance, reinforcing negative sentiment. Phreesia’s growth guidance disappointed. We’re pulling our recommendation.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.